Evidence map›Paper›PMID 35183258›Full record

ArticleBiomarker research2022

FAM83A is a potential biomarker for breast cancer initiation.

Natascia Marino, Rana German, Ram Podicheti, Pam Rockey, George E Sandusky, Constance J Temm, Harikrishna Nakshatri, Rebekah J Addison, Bryce Selman, Sandra K Althouse and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomarker research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Natascia MarinoSusan G. Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA. marinon@iu.edu.ORCID http://orcid.org/0000-0001-6771-8963
Rana GermanSusan G. Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA.
Ram PodichetiCenter for Genomics and Bioinformatics, Indiana University, Bloomington, IN, 47405, USA.
Pam RockeySusan G. Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA.
George E SanduskyPathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Constance J TemmPathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Harikrishna NakshatriDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Rebekah J AddisonPathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Bryce SelmanPathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Sandra K AlthouseDepartment of Biostatistics and Health Data Sciences, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Anna Maria V StornioloSusan G. Komen Tissue Bank at the IU Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA.
Indiana University School of MedicineIndiana University Health · USIndiana University Bloomington · US

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI David W Clapp · 1999 to 2026
$59.3M
Breast Cancer Research Foundation BCRF-19-155Breast Cancer Research Foundation BCRF-20-155NCI NIH HHS P30 CA082709
6 · The paper itself

Abstract

backgroundFamily with sequence similarity 83 member A (FAM83A) presents oncogenic properties in several cancers including breast cancer. Recently, we reported FAM83A overexpression in normal breast tissues from women at high risk of breast cancer. We now hypothesize that FAM83A is a key factor in breast cancer initiation.

methodsImmunohistochemical staining was used to evaluate FAM83A protein levels in both a normal breast tissue microarray (TMA, N = 411) and a breast tumor TMA (N = 349). EGFR staining and its correlation with FAM83A expression were also assessed. Lentivirus-mediated manipulation of FAM83A expression in primary and hTERT-immortalized breast epithelial cells was employed. Biological and molecular alterations upon FAM83A overexpression/downregulation and FAM83A's interaction partners were investigated.

resultsTMA analysis revealed a 1.5-fold increase in FAM83A expression level in breast cancer cases as compared with normal breast tissues (p < 0.0001). FAM83A protein expression was directly correlated with EGFR level in both normal and breast cancer tissues. In in vitro assays, exogenous expression of FAM83A in either primary or immortalized breast epithelial cells promoted cell viability and proliferation. Additionally, Ingenuity Pathway Analysis (IPA) revealed that FAM83A overexpression in primary cells affected the expression of genes involved in cellular morphology and metabolism. Mass spectrometry analysis identified DDX3X and LAMB3 as potential FAM83A interaction partners in primary cells, while we detected FAM83A interaction with cytoskeleton reorganization factors, including LIMA1, MYH10, PLEC, MYL6 in the immortalized cells.

conclusionsThis study shows that FAM83A promotes metabolic activation in primary breast epithelial cells and cell proliferation in both primary and immortalized cells. These findings support its role in early breast oncogenesis.

Indexed as

Breast cancerCell transformationFAM83ANormal breast

Identifiers

PMID35183258
PMCPMC8858535
OpenAlexW4220701187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.